Biotechnology company CSL has posted a full year profit of $US2 billion ($A2.8 billion) and has increased its sales revenue by 7.2 per cent to $US8.8 billion ($A12.4 billion).
CEO and managing director Paul Perreault said in a note to investors that
“I am pleased to report an exceptional result against a backdrop of complex and unexpected challenges brought about by the coronavirus pandemic," he said.
The company also indicated it had the resources to be at the forefront of the battle against COVID-19 and said it had locked down a partnership to develop a possible vaccine.
"No single vaccine or therapeutic approach is going to solve this health crisis; multiple approaches are essential," the company said.
“CSL has been very active in research and development, focusing our response to the global pandemic by finding adjacencies where we can leverage our capabilities, expertise and technologies..
“There are multiple R&D programs and partnerships aimed at fighting COVID-19, including in the areas of vaccines, monoclonal antibodies and plasma therapies.”